SCHEMBL1993515

SCHEMBL1993515

CN(C)C1CCC(Cn2nc(C3=C(c4c[nH]c5sccc45)C(=O)NC3=O)c3ccccc32)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 2/20 0.45
GSK3B P49841 13/20 0.43
PRKCG P05129 11/20 0.43
PRKCB P05771 11/20 0.43
PRKCA P17252 11/20 0.43
PRKCD Q05655 7/20 0.43
KCNH2 Q12809 5/20 0.38
PRKCZ Q05513 4/20 0.38
PIM1 P11309 1/20 0.38
KISS1R Q969F8 1/20 0.37
PRKACA P17612 1/20 0.37
PRKACG P22612 1/20 0.37
PRKACB P22694 1/20 0.37
CNR2 P34972 1/20 0.37
SRC P12931 1/20 0.36
PRKCH P24723 1/20 0.36
PRKCE Q02156 1/20 0.36
CAMK2B Q13554 1/20 0.36
CAMK2G Q13555 1/20 0.36
CAMK2A Q9UQM7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12563848 1.00 CAMK2D (0.45) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL1992218 0.88 CAMK2D (0.49) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL1990076 0.88 CAMK2D (0.48) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL1993511 0.87 CAMK2D (0.45) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL1996421 0.86 CAMK2D (0.50) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL1997361 0.86 CAMK2D (0.45) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL1992211 0.86 CAMK2D (0.40) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL12563790 0.86 CAMK2D (0.40) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL1995677 0.85 CAMK2D (0.49) CAMK2DGSK3BPRKCGPRKCBPRKCA
SCHEMBL1994915 0.85 PRKACA (0.55) CAMK2DGSK3BPRKCGPRKCBPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO CAMK2D 2963/4885GSK3B 2908/4885PRKCG 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.